Cover Image

Cancer-associated fibroblasts mediate resistance to anti-EGFR therapies in cancer

Over the last decade, epidermal growth factor receptor (EGFR)-targeted therapies have transformed the treatment landscape for patients with advanced solid tumors. Despite these advances, resistance to anti-EGFR therapies is still a significant clinical challenge. While cell-autonomous mechanisms of...

Full description

Saved in:

Bibliographic Details
Main Authors:	Shuang Dai (Author), Yingtong Liu (Author), Zheran Liu (Author), Ruidan Li (Author), Feng Luo (Author), Yan Li (Author), Lei Dai (Author), Xingchen Peng (Author)
Format:	Book
Published:	Elsevier, 2024-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database
by: Huaju Yang, et al.
Published: (2023)

Association between Statin Use and Survival in Cancer Patients with Brain Metastasis: Retrospective Analysis from the Chinese Population
by: Yu Min, et al.
Published: (2022)

Assessing the role of lipid-lowering therapy on multi-cancer prevention: A mendelian randomization study
by: Yu Min, et al.
Published: (2023)

FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway
by: Shike Yan, et al.
Published: (2022)

Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
by: Alejandro Ríos-Hoyo, et al.
Published: (2024)

Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer
by: Brian J. Thomas, et al.
Published: (2023)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
by: Keigo Kobayashi
Published: (2023)

MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
by: Chao-Ju Chen, et al.
Published: (2021)

EGFR FISH analysis in colorectal cancer as a tool in selecting patients for antiEGFR monoclonal antibodies therapy
by: Mauro Moroni, et al.
Published: (2011)

Marine-derived EGFR inhibitors: novel compounds targeting breast cancer growth and drug resistance
by: Qi Li, et al.
Published: (2024)

Transformation of adenocarcinoma into small cell lung cancer as one of the mechanisms of acquired resistance to anti-EGFR tyrosine kinase inhibitors
by: O. O. Kovalov, et al.
Published: (2024)

Biomarkers for cancer-associated fibroblasts
by: Chencheng Han, et al.
Published: (2020)

Advances of cancer-associated fibroblasts in liver cancer
by: Hao Peng, et al.
Published: (2022)

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
by: Si-Yang Maggie Liu, et al.
Published: (2023)

Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death
by: Colleen M. Britain, et al.
Published: (2018)

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
by: Pacini L, et al.
Published: (2021)

Cinobufagin Is a Selective Anti-Cancer Agent against Tumors with EGFR Amplification and PTEN Deletion
by: Kunyan He, et al.
Published: (2021)

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
by: Luwei Han, et al.
Published: (2021)

Metastasis-associated fibroblasts: an emerging target for metastatic cancer
by: Zimu Wang, et al.
Published: (2021)

Research Progress on Therapeutic Targeting of Cancer-Associated Fibroblasts to Tackle Treatment-Resistant NSCLC
by: Chenxin Li, et al.
Published: (2022)

Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
by: Jianghua Ding, et al.
Published: (2024)

Acacetin exerts antitumor effects on gastric cancer by targeting EGFR
by: Guangtao Zhang, et al.
Published: (2023)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
by: Xiaoyu Qian, et al.
Published: (2022)

Deciphering the Dynamics of EGFR-TKI Resistance in Lung Cancer: Insights from Bibliometric Analysis
by: Zhou Y, et al.
Published: (2024)

The Application of Inorganic Nanoparticles in Molecular Targeted Cancer Therapy: EGFR Targeting
by: Meng Sun, et al.
Published: (2021)

Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling
by: Najah Albadari, et al.
Published: (2024)

CircHECTD1 mediates pulmonary fibroblast activation HECTD1
by: Han Chu, et al.
Published: (2019)

EGF-mediated EGFR/ERK signaling pathway promotes germinative cell proliferation in Echinococcus multilocularis that contributes to larval growth and development.
by: Zhe Cheng, et al.
Published: (2017)

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
by: Wang Z, et al.
Published: (2022)

MiR-124-3p mediates gastric cancer cell ferroptosis induced by an anti-cancer drug polyphyllin I
by: Fang Zheng, et al.
Published: (2023)

ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer
by: Dantong Sun, et al.
Published: (2021)

Prediction of EGFR Mutation Status in Non-Small Cell Lung Cancer Based on Ensemble Learning
by: Youdan Feng, et al.
Published: (2022)

Inhalable Anti-EGFR Antibody-Conjugated Osimertinib Liposomes for Non-Small Cell Lung Cancer
by: Apoorva Daram, et al.
Published: (2024)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
by: Chen Shi, et al.
Published: (2023)

Repurposing EGFR Inhibitors for Oral Cancer Pain and Opioid Tolerance
by: Maria Daniela Santi, et al.
Published: (2023)

Dorsomorphin attenuates ABCG2-mediated multidrug resistance in colorectal cancer
by: Xiao-Peng Li, et al.
Published: (2024)

Spatial omics accelerate the study of cancer‐associated fibroblasts in non‐small lung cancer
by: Haozhen Liu, et al.
Published: (2024)

Natural product manoalide promotes EGFR-TKI sensitivity of lung cancer cells by KRAS-ERK pathway and mitochondrial Ca2+ overload-induced ferroptosis
by: Yinyun Ni, et al.
Published: (2023)

PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities
by: Xiaohong Liu, et al.
Published: (2024)

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
by: Chenguang Li, et al.
Published: (2018)